U Löbel1,2, S Hwang2, A Edwards2, Y Li3, X Li3, A Broniscer4,5, Z Patay6. 1. Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS220, Memphis, TN, 38105, USA. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA. 6. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS220, Memphis, TN, 38105, USA. zoltan.patay@stjude.org.
Abstract
INTRODUCTION: Based on clinical observations, we hypothesized that in infiltrative high-grade brainstem neoplasms, such as diffuse intrinsic pontine glioma (DIPG), longitudinal metabolic evaluation of the tumor by magnetic resonance spectroscopy (MRS) may be more accurate than volumetric data for monitoring the tumor's biological evolution during standard treatment. METHODS: We evaluated longitudinal MRS data and corresponding tumor volumes of 31 children with DIPG. We statistically analyzed correlations between tumor volume and ratios of Cho/NAA, Cho/Cr, and NAA/Cr at key time points during the course of the disease through the end of the progression-free survival period. RESULTS: By the end of RT, tumor volume had significantly decreased from the baseline (P < .0001) and remained decreased through the last available follow-up magnetic resonance imaging study (P = .007632). However, the metabolic profile of the tumor tissue (Cho/Cr, NAA/Cr, and Cho/NAA ratios) did not change significantly over time. CONCLUSION: Our data show that longitudinal tumor volume and metabolic profile changes are dissociated in patients with DIPG during progression-free survival. Volume changes, therefore, may not accurately reflect treatment-related changes in tumor burden. This study adds to the existing body of evidence that the value of conventional MRI metrics, including volumetric data, needs to be reevaluated critically and, in infiltrative tumors in particular, may not be useful as study end-points in clinical trials. We submit that advanced quantitative MRI data, including robust, MRS-based metabolic ratios and diffusion and perfusion metrics, may be better surrogate markers of key end-points in clinical trials.
INTRODUCTION: Based on clinical observations, we hypothesized that in infiltrative high-grade brainstem neoplasms, such as diffuse intrinsic pontine glioma (DIPG), longitudinal metabolic evaluation of the tumor by magnetic resonance spectroscopy (MRS) may be more accurate than volumetric data for monitoring the tumor's biological evolution during standard treatment. METHODS: We evaluated longitudinal MRS data and corresponding tumor volumes of 31 children with DIPG. We statistically analyzed correlations between tumor volume and ratios of Cho/NAA, Cho/Cr, and NAA/Cr at key time points during the course of the disease through the end of the progression-free survival period. RESULTS: By the end of RT, tumor volume had significantly decreased from the baseline (P < .0001) and remained decreased through the last available follow-up magnetic resonance imaging study (P = .007632). However, the metabolic profile of the tumor tissue (Cho/Cr, NAA/Cr, and Cho/NAA ratios) did not change significantly over time. CONCLUSION: Our data show that longitudinal tumor volume and metabolic profile changes are dissociated in patients with DIPG during progression-free survival. Volume changes, therefore, may not accurately reflect treatment-related changes in tumor burden. This study adds to the existing body of evidence that the value of conventional MRI metrics, including volumetric data, needs to be reevaluated critically and, in infiltrative tumors in particular, may not be useful as study end-points in clinical trials. We submit that advanced quantitative MRI data, including robust, MRS-based metabolic ratios and diffusion and perfusion metrics, may be better surrogate markers of key end-points in clinical trials.
Authors: Katherine E Warren; Tina Y Poussaint; Gilbert Vezina; Darren Hargrave; Roger J Packer; Stewart Goldman; Patrick Y Wen; Ian F Pollack; David Zurakowski; Larry E Kun; Michael D Prados; Stefan Rutkowski; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2013-04-26 Impact factor: 3.167
Authors: Tina Young Poussaint; Mehmet Kocak; Sridhar Vajapeyam; Roger I Packer; Richard L Robertson; Russell Geyer; Daphne Haas-Kogan; Ian F Pollack; Gilbert Vezina; Robert Zimmerman; Soonmee Cha; Zoltan Patay; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-02-04 Impact factor: 12.300
Authors: Anne Laprie; Andrea Pirzkall; Daphne A Haas-Kogan; Soonmee Cha; Anuradha Banerjee; Terry P Le; Ying Lu; Sarah Nelson; Tracy R McKnight Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-01 Impact factor: 7.038
Authors: Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt Journal: Neuroimage Date: 2004-10 Impact factor: 6.556
Authors: Alberto Broniscer; Justin N Baker; Michael Tagen; Arzu Onar-Thomas; Richard J Gilbertson; Andrew M Davidoff; Atmaram S Pai Panandiker; Atmaram Pai Panandiker; Wing Leung; Thomas K Chin; Clinton F Stewart; Mehmet Kocak; Christopher Rowland; Thomas E Merchant; Sue C Kaste; Amar Gajjar Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Susanne Kossatz; Brandon Carney; Melanie Schweitzer; Giuseppe Carlucci; Vesselin Z Miloushev; Uday B Maachani; Prajwal Rajappa; Kayvan R Keshari; David Pisapia; Wolfgang A Weber; Mark M Souweidane; Thomas Reiner Journal: Cancer Res Date: 2017-01-20 Impact factor: 12.701
Authors: S Vajapeyam; D Brown; C Billups; Z Patay; G Vezina; M S Shiroishi; M Law; P Baxter; A Onar-Thomas; J R Fangusaro; I J Dunkel; T Y Poussaint Journal: AJNR Am J Neuroradiol Date: 2020-04-02 Impact factor: 4.966